Medical network - May 24, at present, under the trend of the pharmaceutical industry growth is slowing, in vitro diagnostic (IVD) as a minority can maintain rapid growth of industry, the development is very active. Recently, runda medical plans to buy raylai biology for 1.2 billion yuan, and the gold domain test announced the formal entry into the IVD area. 

 

IVD is a good place to grow 

 

Newspaper 21st century pharmacy, deputy general manager, deputy editor-in-chief Xu Xiaoliang said: "the current clinical diagnostic information about two-thirds from in vitro diagnosis, in vitro diagnosis has become the prevention, diagnosis and treatment of diseases is becoming more and more important part of." 

 

In recent years, the diagnostic industry in China has been developing rapidly. According to incomplete statistics, the market size of China's external diagnostic market is significantly higher than the global average, and the annual compound growth rate is around 20%. According to the national health industry enterprise management association medical inspection industry branch, in 2016, the market size of the diagnostic market in China is about 45 billion yuan. 

 

The global market for external diagnostics is expected to reach $80bn by 2018, according to authorities. For a long time, developed countries and regions such as Europe and the United States, is a key market for IVD consumption, but in recent years, IVD market in China, India and other emerging countries got a rapid promotion. In vitro diagnostic market scale in China about 28.7 billion yuan in 2015, accounted for about 7% global IVD total consumer market, consumption amount is about $2 per person in the left and right sides, and the developed economies compared to about $30 per capita consumption amount gap is still large. In addition, in the domestic IVD market, imported instruments and reagents account for more than 50% of the market, and the future import substitution space is huge. In the next five years, the IVD industry is expected to keep growing at a relatively fast pace of over 15 percent in the country. 

 

In addition, in vitro diagnostic industry development is more and more under the influence of national policies and laws and regulations, the government continued to improve the regulation of the industry, improve the regulatory measures at the same time, also have issued a series of promote and promote the development of industry policy. As the national "much starker choices-and graver consequences-in" health and health planning, "healthy China 2030" planning outline, classification of diagnosis and treatment policy implementation step by step, will bring new opportunities for the rapid development of in vitro diagnostic industry. 

 

Rigid demand and policy dividends will accelerate our country's rapid development of IVD. Industry analysis, whether from the market scale or the growth rate, our country IVD industry has the huge growth space. The development of the IVD market also attracts more and more enterprise layout. "The opening of guangzhou jinqirui biotechnology co., LTD. Is a sign that the gold domain will officially enter the IVD industry." The relevant person in charge of golden field, said as a golden field inspection "+" key step development strategy of be born, Jin Qi implementation platform will creat the in vitro diagnostic products, continue to strengthen the cooperation with many international famous enterprises, colleges and universities, the overall transformation of scientific and technological incubator and fall to the ground in the field of IVD. 

 

Domestic companies are looking for breakthroughs 

 

With more and more internal and external diagnostic enterprises, competition is fierce. From the point of the competitive environment, multinational companies in our country in vitro diagnostic monopoly in the high-end market, using the advantage of products, technologies and services and so on various aspects, increasing investment in China, especially in the domestic tertiary hospitals, in the high-end market has a larger market share. However, most enterprises in the country mainly produce middle and low end diagnostic products, and have not yet developed a stable market pattern. 

 

Analysis of the personage inside course of study, although the in vitro diagnostic domestic enterprises are numerous, but most of the enterprise product technology content is low, business scope of a single, customers concentrated in the low-end market. At the same time, the domestic enterprise is small, the market concentration is not high, the scale benefit is still to be promoted. 

 

Notable is, the current domestic part of the in vitro diagnostic companies are actively toward diversified development, relying on the original advantage continuously expand production areas, strengthen independent research and development production, and enhance market competitiveness. In addition, domestic extracorporeal diagnostic enterprises are also actively moving into the international market, especially in developing countries such as Asia and Africa. 

 

"With foreign IVD enterprises' instrument + reagent 'integration development pattern, domestic manufacturer is mainly engaged in production and diagnostic reagents as original products in the domestic overseas agents, now part of the excellent r&d and production of domestic companies are also beginning to instrument, model for future products will be made by pure reagent to the integration of instruments and reagents evolution." In Xu Xiaoliang point of view, the current domestic market, in vitro diagnostic includes not only international giants such as Siemens, roche, abbott laboratories, Johnson &johnson, many excellent domestic enterprises are to stand out. There are about 400 enterprises in our country in vitro diagnosis reagents, about 20 enterprises with annual sales of over 100 million yuan. 

 

According to the progress of biological, dean, diagnosis, and a number of leading in maike creatures in vitro diagnostic released 2016 annual report data of listed companies, its growth performance is good, and said it will continue to improve product technical performance and quality, rich product variety. Through the use of domestic policy support and the increasing regulation of industry regulation, the breakthrough and import substitution of high-end extracorporeal diagnosis field are realized. 

 

The relevant person in charge of golden field said: "the current domestic market mainly for foreign brand occupy in vitro diagnostic. We will vigorously the introduction of domestic and international advanced biotechnology and start-up projects with advanced technology level, innovative research and development a number of joint international new products and new technology, many good results which conversion. Unlike foreign brand, the international first-class technology diagnosis will be based in Asia, especially China population characteristics of disease, so as to establish the Chinese people's disease big sample library and database."